Cagrilintide: The Amylin Analogue Behind CagriSema
A plain-English, evidence-first look at cagrilintide — the long-acting amylin analogue, its trial record, doses studied, and why it is almost never used alone.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-06-13Strong, manufacturer-funded trial evidence — but overwhelmingly for the cagrilintide–semaglutide combination (CagriSema), not amylin agonism alone. Investigational as a standalone; the ‘gentler amylin-only’ narrative is not backed by approved-product evidence.
Well-engineered long-acting amylin (and calcitonin) receptor agonist; mechanistically additive to GLP-1.
Discovery/engineering work supports the long-acting design; efficacy is human-trial-led.
Phase 2 monotherapy RCT (~10.8%) and large Phase 3 CagriSema RCTs (REDEFINE 1/2, NEJM 2025); standalone evidence is thinner than the combination.
Meaningful — ~10.8% as monotherapy, ~20.4% as CagriSema — but the standout numbers are the combination, not amylin alone.
Reasonable trial data (GI-dominant; a thorough-QT study found no relevant QTc effect); long-term standalone data limited.
Investigational as a standalone; CagriSema filed with the FDA (Dec 2025), decision expected 2026.
Solid for the combination; lower for cagrilintide as a standalone agent.
Investigational standalone (not approved anywhere); realistic supply is unregulated grey-market.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
A long-acting amylin analogue (not a GLP-1 drug). The strong trial evidence is overwhelmingly for the cagrilintide–semaglutide combination (CagriSema), not cagrilintide alone; standalone evidence is thinner.
Safety snapshot
Trial safety is GI-dominant; standalone long-term data are limited, and the realistic non-trial supply is unregulated.
Regulatory & legality
Investigational and not approved as a standalone anywhere; the combination has been filed but not approved.
Where claims can exceed the evidence
The 'gentler amylin-only' framing is not backed by approved-product evidence; the headline numbers belong to the combination.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
Cagrilintide is one of the more interesting molecules in the current obesity pipeline, partly because it is rarely talked about on its own terms. Most people encounter it as the "cagri" half of CagriSema — Novo Nordisk's fixed-dose combination with semaglutide that posted around 20% weight loss in a large phase 3 trial [4]. But cagrilintide is a distinct drug with its own mechanism, its own trial history, and its own monotherapy data showing roughly 10.8% weight loss over 26 weeks [2].
The headline facts: cagrilintide is a long-acting amylin analogue dosed once weekly by subcutaneous injection. It is investigational — not approved anywhere as a standalone product. The combination CagriSema completed its pivotal phase 3 programme, and Novo Nordisk filed a New Drug Application with the US FDA on 18 December 2025, with review expected during 2026 [12]. If cleared, it would be the first injectable GLP-1 plus amylin analogue combination [12]. This article covers what cagrilintide is, what the evidence actually shows, and why the standalone story is thinner than the combination story.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
Adipotide: The Fat-Vessel Killer That Stalled in Humans
Adipotide melts white fat by destroying the blood vessels feeding it. Striking animal data, zero human efficacy evidence, and kidney toxicity that ended its development.
AOD-9604: The Fat-Loss Peptide That Failed Its Own Trial
AOD-9604 is a growth-hormone fragment with strong fat-loss data in animals — but its pivotal human obesity trial failed, and it was never approved as a medicine.
Mazdutide: The First GLP-1/Glucagon Dual Agonist, and What the Trials Actually Show
Mazdutide is a once-weekly GLP-1/glucagon dual agonist with strong phase 3 evidence (up to ~20% weight loss) — but it is China-only and largely untested elsewhere.
Retatrutide: The Triple Agonist Pushing Weight Loss Past Everything Before It
An evidence-first look at retatrutide, the investigational GLP-1/GIP/glucagon triple agonist posting the largest weight-loss numbers seen in any incretin trial to date.